WeVote
Log In

Bill

Bill

SF 3306

Prior authorization on medications prescribed for antineoplastic cancer treatment prohibition; prior authorization denials based on timing of the provided health care service prohibition; expedited prior authorization review for prescriptions that have previously been authorized or covered requirement

2025-2026 Regular Session Introduced by Liz Boldon and 1 co-sponsor

Minnesota bill prohibits insurers from requiring prior authorization for cancer medications and mandates expedited review for previously-covered prescriptions to reduce treatment delays.

Author added Boldon
#healthandhealthdepartment #insurance #insurance-health
0
WeVote Research Nonpartisan
Bill Summary · SF 3306

Legislative bill overview

SF 3306 prohibits health insurers from requiring prior authorization for medications used in cancer treatment (antineoplastic drugs) and bars insurers from denying prior authorization based solely on the timing of when a healthcare service was provided. The bill also mandates expedited review processes for prescriptions that have previously been authorized or covered by the same insurer.

Why is this important

Cancer patients often face treatment delays when insurers require advance approval before dispensing expensive medications, potentially compromising therapeutic outcomes when timing is critical. These restrictions can affect thousands of Minnesotans with cancer diagnoses and establish precedent for how quickly insurers must respond to medication requests, directly impacting access to time-sensitive care.

Potential points of contention

  • Cost implications: Insurers may argue that removing prior authorization requirements eliminates their ability to manage drug costs and prevent inappropriate prescribing, potentially increasing premiums for all enrollees
  • Scope definition: Ambiguity about which drugs qualify as "antineoplastic" cancer treatment could create disputes; the bill doesn't clearly define whether supportive care medications are included
  • Expedited review burden: Requiring expedited reauthorization for previously-approved drugs may strain insurer administrative capacity, raising feasibility concerns about implementation timelines

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.